{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Personalis, Inc. Hits Day High with 8.1% Surge in Strong Intraday Performance
Personalis, Inc. has seen significant short-term gains, with an 8.1% increase today and a notable rise over the past week and month. Despite these recent successes, the company faces long-term challenges, including declining operating profit and negative results for the last four quarters, alongside a concerning cash flow situation.
Personalis, Inc. Hits Day Low of $10.39 Amid Price Pressure
Personalis, Inc. faced a notable stock decline amid a challenging trading session, contrasting with broader market trends. While the company has shown strong monthly performance, it struggles with long-term financial health, reflected in significant operating profit declines and negative cash flow, raising concerns about its sustainability.
Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64%
Personalis, Inc. has achieved a new 52-week high, reflecting a significant year-over-year performance increase. With a market capitalization of USD 710 million, the company operates in a competitive biotechnology sector, despite facing challenges such as negative return on equity and a lack of dividend yield.
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price
Personalis, Inc. has seen notable stock activity, with a significant increase today and impressive growth over the past week and month. Despite challenges such as declining operating profit and negative quarterly results, the company's market capitalization stands at USD 710 million, reflecting its volatility and potential in the market.
Personalis, Inc. Hits New 52-Week High of $8.93, Up 546% Year-Over-Year
Personalis, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 8.93 on October 15, 2025, reflecting a significant year-over-year performance increase. The company, with a market capitalization of USD 472 million, is currently operating at a loss and has a unique financial structure.
Personalis, Inc. Hits New 52-Week High of $8.70, Up 557.58%
Personalis, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 8.70 on October 8, 2025, reflecting a significant performance improvement. The company has seen a 557.58% stock increase over the past year, despite being loss-making and having a market cap of USD 472 million.
Is Personalis, Inc. technically bullish or bearish?
As of September 11, 2025, Personalis, Inc. shows a bullish technical trend overall, despite mixed short-term signals and underperformance compared to the S&P 500.
Is Personalis, Inc. technically bullish or bearish?
As of June 2, 2025, Personalis, Inc. shows a mildly bullish trend overall, supported by positive MACD and Bollinger Bands indicators, but caution is advised due to a bearish weekly RSI and mixed signals from daily moving averages.
Who are in the management team of Personalis, Inc.?
As of March 2022, the management team of Personalis, Inc. includes Jonathan MacQuitty (Independent Chairman), John West (CEO), and several Independent Directors: Patrick Balthrop, A. Blaine Bowman, Alan Colowick, Karin Eastham, and Kenneth Ludlum. They oversee the company's strategic direction and operations.
What does Personalis, Inc. do?
Personalis, Inc. is a cancer genomics company that provides molecular data to develop personalized cancer therapies. As of March 2025, it reported net sales of $21 million and a net loss of $16 million, with a market cap of $550.27 million.
How big is Personalis, Inc.?
As of Jun 18, Personalis, Inc. has a market capitalization of 550.27 million and reported net sales of 85.70 million with a net profit of -84.07 million over the latest four quarters. Shareholder's funds are 202.96 million, and total assets amount to 270.27 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
